Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
Total Valuation
Avadel Pharmaceuticals has a market cap or net worth of $2.24B. The enterprise value is $1.49B.
Market Cap$2.24B
Enterprise Value$1.49B
Share Statistics
Avadel Pharmaceuticals has 97,656,660 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding97,656,660
Owned by Insiders1.06%
Owned by Institutions35.35%
Financial Efficiency
Avadel Pharmaceuticals’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -35.79%.
Return on Equity (ROE)-0.66
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-35.79%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee899.56K
Profits Per Employee-259.74K
Employee Count188
Asset Turnover1.03
Inventory Turnover0.75
Valuation Ratios
The current PE Ratio of Avadel Pharmaceuticals is ―. Avadel Pharmaceuticals’s PEG ratio is 0.27.
PE Ratio―
PS Ratio5.91
PB Ratio13.54
Price to Fair Value13.54
Price to FCF-21.32
Price to Operating Cash Flow331.83
PEG Ratio0.27
Income Statement
In the last 12 months, Avadel Pharmaceuticals had revenue of 169.12M and earned -48.83M in profits. Earnings per share was -0.51.
Revenue169.12M
Gross Profit153.84M
Operating Income-42.40M
Pretax Income-49.08M
Net Income-48.83M
EBITDA-35.57M
Earnings Per Share (EPS)-0.51
Cash Flow
In the last 12 months, operating cash flow was 35.60M and capital expenditures -191.76K, giving a free cash flow of 35.41M billion.
Operating Cash Flow35.60M
Free Cash Flow35.41M
Free Cash Flow per Share0.36
Dividends & Yields
Avadel Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change105.56%
50-Day Moving Average17.54
200-Day Moving Average11.86
Relative Strength Index (RSI)80.63
Average Volume (3m)4.27M
Important Dates
Avadel Pharmaceuticals upcoming earnings date is Mar 9, 2026, Before Open (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 9, 2026
Ex-Dividend Date―
Financial Position
Avadel Pharmaceuticals as a current ratio of 2.75, with Debt / Equity ratio of 3.00%
Current Ratio2.75
Quick Ratio2.33
Debt to Market Cap0.04
Net Debt to EBITDA1.40
Interest Coverage Ratio-3.91
Taxes
In the past 12 months, Avadel Pharmaceuticals has paid -247.00K in taxes.
Income Tax-247.00K
Effective Tax Rate<0.01
Enterprise Valuation
Avadel Pharmaceuticals EV to EBITDA ratio is -26.72, with an EV/FCF ratio of -20.26.
EV to Sales5.62
EV to EBITDA-26.72
EV to Free Cash Flow-20.26
EV to Operating Cash Flow-20.26
Balance Sheet
Avadel Pharmaceuticals has $91.58M in cash and marketable securities with $37.38M in debt, giving a net cash position of $54.20M billion.
Cash & Marketable Securities$91.58M
Total Debt$37.38M
Net Cash$54.20M
Net Cash Per Share$0.55
Tangible Book Value Per Share$0.60
Margins
Gross margin is 89.64%, with operating margin of -25.07%, and net profit margin of -28.87%.
Gross Margin89.64%
Operating Margin-25.07%
Pretax Margin-29.02%
Net Profit Margin-28.87%
EBITDA Margin-21.03%
EBIT Margin-22.62%
Analyst Forecast
The average price target for Avadel Pharmaceuticals is $19.93, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$19.93
Price Target Upside-13.05% Downside
Analyst ConsensusHold
Analyst Count10
Revenue Growth Forecast79.88%
EPS Growth Forecast99.60%